Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Endo Int'l Plc (ENDP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,914,296
  • Shares Outstanding, K 223,930
  • Annual Sales, $ 3,469 M
  • Annual Income, $ -2,035,430 K
  • 36-Month Beta 0.71
  • Price/Sales 1.13
  • Price/Cash Flow 2.09
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 0.59
  • Number of Estimates 8
  • High Estimate 0.68
  • Low Estimate 0.52
  • Prior Year 0.91
  • Growth Rate Est. (year over year) -35.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.67 +12.89%
on 09/18/18
18.16 -2.59%
on 10/10/18
+1.70 (+11.33%)
since 09/14/18
3-Month
10.52 +68.16%
on 07/17/18
18.16 -2.59%
on 10/10/18
+7.03 (+67.52%)
since 07/16/18
52-Week
5.27 +235.67%
on 04/04/18
18.16 -2.59%
on 10/10/18
+9.97 (+132.15%)
since 10/16/17

Most Recent Stories

More News
Rigel (RIGL) Gets EMA Acceptance for Thrombocytopenia Drug

The EMA validates Rigel Pharmaceuticals' (RIGL) marketing application for thrombocytopenia drug, Tavalisse.

ENDP : 17.72 (+1.37%)
RIGL : 3.05 (+1.33%)
ACRS : 12.82 (-4.40%)
UTHR : 124.26 (+0.68%)
Excellent Growth Seen in "Post-Operative Pain Management Market" by 2023 - Competitive Landscape and Revenue Status by Most Prominent Players

VRX.TO : 30.80 (-3.33%)
ENDP : 17.72 (+1.37%)
LLY : 110.56 (-0.05%)
BAX : 70.94 (+0.10%)
NVS : 84.64 (+1.79%)
GSK : 39.63 (+1.93%)
Endo Presents Data on the Perception and Measurement of Cellulite Severity at the American Society for Dermatologic Surgery (ASDS) Annual Meeting

Endo International plc (NASDAQ: ENDP) today announced that data regarding the evaluation and rating of cellulite severity will be presented at the Annual Meeting of the American Society for Dermatologic...

ENDP : 17.72 (+1.37%)
Best ETFs & Stocks From the Top Sector of Q3

Healthcare was the best-performing sector of the third quarter, jumping 14.1% - its highest quarterly gain since the first quarter of 2013.

IRMD : 26.54 (-3.77%)
RARX : 15.54 (+1.24%)
ARKG : 29.04 (+0.90%)
ENDP : 17.72 (+1.37%)
IHF : 193.30 (+1.60%)
FXH : 79.56 (+1.70%)
IDXG : 1.34 (unch)
IYH : 195.48 (+1.76%)
CSBR : 12.25 (-2.80%)
Endo Recalls 2 Lots of Robaxin Tablets Due to Labeling Error

Endo International (ENDP) recalls two lots of Robaxin 750mg Tablets due to wrong dosing information on the label.

ENDP : 17.72 (+1.37%)
AKBA : 8.75 (+1.63%)
CSBR : 12.25 (-2.80%)
BSTC : 60.50 (-0.77%)
Best ETFs & Stocks From the Top Sector of Q3

Healthcare was the best-performing sector of the third quarter, jumping 14.1% - its highest quarterly gain since the first quarter of 2013.

IRMD : 26.54 (-3.77%)
RARX : 15.54 (+1.24%)
ARKG : 29.04 (+0.90%)
ENDP : 17.72 (+1.37%)
IHF : 193.30 (+1.60%)
FXH : 79.56 (+1.70%)
IDXG : 1.34 (unch)
IYH : 195.48 (+1.76%)
CSBR : 12.25 (-2.80%)
Endo to Announce Third-Quarter 2018 Financial Results

Endo International plc will announce its third-quarter 2018 financial results on November 8, 2018 and members of its senior management team will host a conference call and webcast at 8:00 a.m. ET before...

ENDP : 17.72 (+1.37%)
Forget Mylan, Invest in These 3 Generic/Drug Stocks Instead

Given the recent spate of setbacks suffered by Mylan (MYL), we suggest investing in better-ranked generic/drug companies with favorable growth profile.

MYL : 32.87 (+1.54%)
ENDP : 17.72 (+1.37%)
MNK : 27.36 (+0.66%)
TEVA : 21.98 (+1.10%)
EVOK : 2.58 (unch)
Has Endo International plc (ENDP) Outpaced Other Medical Stocks This Year?

Is (ENDP) Outperforming Other Medical Stocks This Year?

ENDP : 17.72 (+1.37%)
Endo Pharmaceuticals Issues Voluntary Nationwide Recall for Two Lots of Robaxin® 750mg Tablets 100 Count Bottle Packs Due to Incorrect Daily Dosing Information on Label

Endo International plc (NASDAQ: ENDP) today announced that one of its operating companies, Endo Pharmaceuticals Inc., is voluntarily recalling two lots of Robaxin® (methocarbamol tablets, USP) 750mg Tablets...

ENDP : 17.72 (+1.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade ENDP with:

Business Summary

Endo International plc is a global specialty healthcare company. It develops, manufactures, markets, and distributes quality branded pharmaceutical and generic products as well as medical devices. Endo offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova,...

See More

Key Turning Points

2nd Resistance Point 18.09
1st Resistance Point 17.79
Last Price 17.72
1st Support Level 17.31
2nd Support Level 17.13

See More

52-Week High 18.16
Last Price 17.72
Fibonacci 61.8% 13.24
Fibonacci 50% 11.72
Fibonacci 38.2% 10.19
52-Week Low 5.27

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar